Gilead Sciences Inc

Latest stories

6h
Business Wire
Ergebnisse der AMBITION-Studie zur Erstbehandlung mit Letairis und Tadalafil bei pulmonalarterieller Hypertonie im The New England Journal of Medicine veröffentlichtFOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Science
Ergebnisse der AMBITION-Studie zur Erstbehandlung mit Letairis und Tadalafil bei pulmonalarterieller Hypertonie im The New England Journal of Medicine veröffentlicht
Business Wire / Posted 6 hours ago
FOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD) hat heute detaillierte Ergebnisse aus der AMBITION-Studie bekannt gegeben. Es handelt sich um eine randomisierte Doppelblind-Multizentrumsstudie... Read more
794 related stories
6h
Business Wire
Les résultats de l'étude AMBITION évaluant un traitement de première ligne combinant Letairis et Tadalafil dans la prise en charge de l'hypertension artérielle pulmonaire sont publiés dans The New England Journal of MedicineFOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
Les résultats de l'étude AMBITION évaluant un traitement de première ligne combinant Letairis et Tadalafil dans la prise en charge de l'hypertension artérielle pulmonaire sont publiés dans The New England Journal of Medicine
Business Wire / Posted 6 hours ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd'hui les résultats détaillés de l’étude AMBITION (une étude multicentrique randomisée en double aveugle d’une polythérapie de première ligne à base... Read more
56 related stories
13h
Business Wire
Resultaten van het AMBITION-onderzoek van de eerstelijnsbehandeling met Letairis en Tadalafil van pulmonale arteriële hypertensie gepubliceerd in The New England Journal of MedicineFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Resultaten van het AMBITION-onderzoek van de eerstelijnsbehandeling met Letairis en Tadalafil van pulmonale arteriële hypertensie gepubliceerd in The New England Journal of Medicine
Business Wire / Posted 13 hours ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag uitgebreide resultaten bekendgemaakt van het AMBITION-onderzoek (een gerandomiseerd, dubbelblind, in meerdere centra uitgevoerd onderzoek van de eerstelijns... Read more
16 related stories
1d
Business Wire
I risultati derivati dallo studio AMBITION su Letairis e Tadalafil come terapia di prima linea per il trattamento dell'ipertensione polmonare arteriosa sono stati pubblicati nella rivista The New England Journal of MedicineFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD)
I risultati derivati dallo studio AMBITION su Letairis e Tadalafil come terapia di prima linea per il trattamento dell'ipertensione polmonare arteriosa sono stati pubblicati nella rivista The New England Journal of Medicine
Business Wire / Posted yesterday
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) ha comunicato in data odierna i risultati dettagliati emersi dallo studio AMBITION (uno studio multicentrico, randomizzato, in doppio cieco sul regime combinato a base di... Read more
20 related stories
1d
Investopedia
ProShares UltraShort Nasdaq BiotechThe ETF (Nasdaq: BIS) tracks the Nasdaq Biotechnology Index. This fund seeks t
ProShares UltraShort Nasdaq Biotech
Investopedia / Posted yesterday
The ETF (Nasdaq: BIS) tracks the Nasdaq Biotechnology Index. This fund seeks to reproduce returns equal to -200% of the daily returns of that index using traditional inverse ETF positions. BIS is the sister fund of... Read more
2 related stories
2d
Business Wire
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of MedicineFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
Business Wire / Posted 2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in... Read more
4d
Investopedia
Healthcare M&A and Prescription Drug PricesIn 2015, there has been a high level of mergers and acquisition (M&A) activity
Healthcare M&A and Prescription Drug Prices
Investopedia / Posted 4 days ago
In 2015, there has been a high level of mergers and acquisition (M&A) activity in the health care sector among both health insurers and drug companies. Many consumers are wondering what effect these mergers will have on their health care plans and... Read more
7d
Investopedia
10 Overlooked Growth Stocks to Consider (ADBE,UA,NFLX)It’s difficult to find high-potential opportunities in the current market envir
10 Overlooked Growth Stocks to Consider (ADBE,UA,NFLX)
Investopedia / Posted 7 days ago
It’s difficult to find high-potential opportunities in the current market environment, but it’s not impossible. Prior to moving on and revealing these potential opportunities, there are a couple of things to note. Since we’re heading for a... Read more
7d
Business Wire
Europäische Arzneimittelagentur validiert Antrag auf Marktzulassung von Gilead für Einzeltablettentherapie aus Rilpivirin, Emtricitabin und Tenofoviralafenamid (R/F/TAF) zur Behandlung von HIVFOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Science
Europäische Arzneimittelagentur validiert Antrag auf Marktzulassung von Gilead für Einzeltablettentherapie aus Rilpivirin, Emtricitabin und Tenofoviralafenamid (R/F/TAF) zur Behandlung von HIV
Business Wire / Posted 7 days ago
FOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences Inc. (NASDAQ: GILD) hat heute bekannt gegeben, dass sein Antrag auf Marktzulassung für ein einmal täglich einzunehmendes Einzeltablettenprüfpräparat bestehend aus 200 mg... Read more
794 related stories
7d
Business Wire
European Medicines Agency valideert Gilead’s aanvraag voor vergunning voor het in de handel brengen van het enkeltabletregime dat rilpivirine, emtricitabine en tenofovir alafenamide (R/F/TAF) bevat voor hiv-behandeling.FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
European Medicines Agency valideert Gilead’s aanvraag voor vergunning voor het in de handel brengen van het enkeltabletregime dat rilpivirine, emtricitabine en tenofovir alafenamide (R/F/TAF) bevat voor hiv-behandeling.
Business Wire / Posted 7 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag bekendgemaakt dat de vergunning voor het in de handel brengen (Marketing Authorization Application, MAA) voor een onderzoeksregime van één maal daags een... Read more
12 related stories
8d
Business Wire
L'Agenzia europea per i medicinali conferma la domanda di autorizzazione alla commercializzazione per un regime monocompressa contenente rilpivirina, emtricitabina e tenofovir alafenamide (R/F/TAF) per il trattamento da infezione HIV di GileadFOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) h
L'Agenzia europea per i medicinali conferma la domanda di autorizzazione alla commercializzazione per un regime monocompressa contenente rilpivirina, emtricitabina e tenofovir alafenamide (R/F/TAF) per il trattamento da infezione HIV di Gilead
Business Wire / Posted 8 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ha annunciato oggi che la domanda di autorizzazione alla commercializzazione per un regime monocompressa che combina emtricitabina 200 mg, tenofovir alafenamide 25 mg e... Read more
15 related stories
11d
Santa Fe Reporter
AIDS Care Pioneer Trevor Hawkins to Leave Santa FeAfter nearly 30 years as a leader in New Mexico’s network of caring for people
AIDS Care Pioneer Trevor Hawkins to Leave Santa Fe
Santa Fe Reporter / Posted 11 days ago
After nearly 30 years as a leader in New Mexico’s network of caring for people with HIV and AIDS, Dr. Trevor Hawkins is leaving the state to take a job with one of the world’s leading manufacturers of drugs to treat the disease. While the move... Read more
14d
Denver Post
With half-dozen employees, GlobeImmune weighs saleTwo months after GlobeImmune Inc.'s hepatitis B drug failed a mid-stage study,
With half-dozen employees, GlobeImmune weighs sale
Denver Post / Posted 14 days ago
Two months after GlobeImmune Inc.'s hepatitis B drug failed a mid-stage study, the Louisville-based drug developer is running at a skeleton crew six people in size and is exploring a potential sale. GlobeImmune on Friday reported its second-quarter... Read more
14d
Investopedia
Celgene Vs. Gilead: Vetting for the Best Biopharma (CELG,GILD,JUNO,RCPT)Celgene Corporation (CELG) and Gilead Sciences, Inc. (GILD) are two of the larg
Celgene Vs. Gilead: Vetting for the Best Biopharma (CELG,GILD,JUNO,RCPT)
Investopedia / Posted 14 days ago
Celgene Corporation (CELG) and Gilead Sciences, Inc. (GILD) are two of the largest drug companies in the pharmaceutical sector. There are many similarities between the companies. Both have had blockbuster drugs that created strong revenues. Both have... Read more
15d
Boulder Daily Camera
GlobeImmune hires adviser, eyes 'strategic alternatives' in wake of hepatitis B drug failureLouisville- based GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company
GlobeImmune hires adviser, eyes 'strategic alternatives' in wake of hepatitis B drug failure
Boulder Daily Camera / Posted 15 days ago
Louisville- based GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company developing products to treat cancer and infectious diseases, announced Thursday morning that it has engaged Cantor Fitzgerald & Co. as its financial adviser to assist in... Read more
21d
The Globe and Mail
U.S. health care stocks: Time for a checkupThe five stocks that made it through the screens were Gilead Sciences Inc., Car
U.S. health care stocks: Time for a checkup
The Globe and Mail / Posted 21 days ago
The five stocks that made it through the screens were Gilead Sciences Inc., Cardinal Health Inc., Amgen Inc., Express Scripts Holding Co. and UnitedHealth Group Inc. In October, 2013, I learned the hard way that Canadian investors have little or no... Read more
22d
Worcester Telegram & Gazette
Stocks fall as media shares tumbleU.S. stocks declined Thursday for the fourth time in five sessions, as results
Stocks fall as media shares tumble
Worcester Telegram & Gazette / Posted 22 days ago
U.S. stocks declined Thursday for the fourth time in five sessions, as results from Viacom Inc. and Twenty-First Century Fox Inc. disappointed, sending media shares toward the biggest two-day loss since 2008.Viacom and Fox slumped at least 9.8... Read more
6 related stories
22d
Market Watch
Biotech sector takes a beating, with some charts warning of further lossesBiotechnology stocks are taking a beating Thursday, as a selloff in the broad m
Biotech sector takes a beating, with some charts warning of further losses
Market Watch / Posted 22 days ago
Biotechnology stocks are taking a beating Thursday, as a selloff in the broad market sends investors scurrying from riskier sectors. Some chart watchers see warning signs that the sector's long run of outperformance may finally be near an end. The... Read more
24d
Business Insurance
Insurers, PBMs continue to fight for bigger, better drug price discountsHealth insurers and pharmacy benefit managers are hoping recent mergers and the
Insurers, PBMs continue to fight for bigger, better drug price discounts
Business Insurance / Posted 24 days ago
Health insurers and pharmacy benefit managers are hoping recent mergers and their growing market clout will help them win steeper drug discounts in their ongoing war with the pharmaceutical industry over specialty drug pricing. However, they're... Read more
28d
Business Wire
Gilead Sciences maakt financiële resultaten tweede kwartaal 2015 bekendFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences maakt financiële resultaten tweede kwartaal 2015 bekend
Business Wire / Posted 28 days ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag haar bedrijfsresultaten bekendgemaakt voor het kwartaal dat eindigde op 30 juni 2015. De volgende financiële resultaten zijn een jaar-op-jaar vergelijking... Read more
17 related stories
28d
The Globe and Mail
The high-stakes battle of medications, insurers and the governmentEvery day, 10-year-old Katharina McGregor takes two white capsules with breakfa
The high-stakes battle of medications, insurers and the government
The Globe and Mail / Posted 28 days ago
Every day, 10-year-old Katharina McGregor takes two white capsules with breakfast and two with dinner. Katha, as she is called, has a rare genetic disease and the pills have let her swim and sing and watch the movies she loves. But they come at a... Read more
28d
Business Wire
Gilead Sciences annonce ses résultats financiers pour le deuxième trimestre 2015FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD)
Gilead Sciences annonce ses résultats financiers pour le deuxième trimestre 2015
Business Wire / Posted 28 days ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui ses résultats d’exploitation pour le trimestre clos le 30 juin 2015. Les résultats financiers qui suivent comparent les résultats du deuxième... Read more
97 related stories
28d
Business Wire
Gilead Sciences gibt Finanzergebnisse für zweites Quartal 2015 bekanntFOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc
Gilead Sciences gibt Finanzergebnisse für zweites Quartal 2015 bekannt
Business Wire / Posted 28 days ago
FOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD), hat heute seine Betriebsergebnisse für das am 30. Juni 2015 beendete Quartal bekannt gegeben. Die folgenden Finanzergebnisse sind ein Vorjahresvergleich... Read more
794 related stories
30d
Market Watch
Profit at drug wholesaler McKesson jumps 43%McKesson Corp. said its profit for the June quarter rose 43% and the company in
Profit at drug wholesaler McKesson jumps 43%
Market Watch / Posted 30 days ago
McKesson Corp. said its profit for the June quarter rose 43% and the company increased its dividend to 28 cents from 24 cents. The drug wholesaler said revenue rose 9.4% to $47.55 billion, compared with expectations of analysts polled by Thomson... Read more
30d
Business Wire
Gilead Sciences anuncia resultados del segundo trimestre, 2015FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences anuncia resultados del segundo trimestre, 2015
Business Wire / Posted 30 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado los resultados de sus operaciones correspondientes al segundo trimestre cerrado el 30 de junio, 2015. Los siguientes resultados financieros representan una... Read more
300 related stories
30d
Business Wire
Gilead Sciences anuncia dividendo del tercer trimestre, 2015FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences anuncia dividendo del tercer trimestre, 2015
Business Wire / Posted 30 days ago
FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado que el Consejo de Administración de la empresa ha declarado un dividendo en efectivo de $0,43 por acción de las acciones ordinarias correspondiente al tercer... Read more
300 related stories
1m
Business Wire
Gilead Sciences gibt Dividenden für Drittes Quartal 2015 bekanntFOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc
Gilead Sciences gibt Dividenden für Drittes Quartal 2015 bekannt
Business Wire / Posted a month ago
FOSTER CITY, Kalifornien--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD) hat heute bekannt gegeben, dass der Vorstand des Unternehmens eine Bardividende in Höhe von 0,43 US-Dollar je Stammaktie für das dritte Quartal 2015... Read more
794 related stories
1m
Business Wire
Gilead Sciences kondigt dividend aan voor het derde kwartaal 2015FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences kondigt dividend aan voor het derde kwartaal 2015
Business Wire / Posted a month ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag bekendgemaakt dat de Board of Directors van het bedrijf een dividend in contanten van $ 0,43 per aandeel gewoon aandeel heeft gedeclareerd voor het derde... Read more
17 related stories
1m
Business Wire
Gilead Sciences annonce son dividende du troisième trimestre 2015FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)
Gilead Sciences annonce son dividende du troisième trimestre 2015
Business Wire / Posted a month ago
FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) a annoncé aujourd'hui que le conseil d'administration de la société a déclaré un dividende en numéraire de 0,43 USD par action pour le troisième trimestre 2015. Ce... Read more
97 related stories
1m
KOB 4 Albuquerque
Gilead beats Street 2Q forecasts on surge in sales, profitCreated: 07/28/2015 3:21 PM By: By LINDA A. JOHNSON Blockbuster hepatitis C m
Gilead beats Street 2Q forecasts on surge in sales, profit
KOB 4 Albuquerque / Posted a month ago
Created: 07/28/2015 3:21 PM By: By LINDA A. JOHNSON Blockbuster hepatitis C medicine Harvoni lifted Gilead Sciences' second-quarter profit by 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales... Read more
156 related stories
1m
Market Watch
Express Scripts raises outlook as profit beatsExpress Scripts Holding Co. on Tuesday raised its guidance as earnings came in
Express Scripts raises outlook as profit beats
Market Watch / Posted a month ago
Express Scripts Holding Co. on Tuesday raised its guidance as earnings came in better than expected for the June quarter. Shares increased 2.6% in recent after-hours trading. Express Scripts, the largest manager of U.S. prescription-drug benefits,... Read more
1m
Salon.com
Gilead beats Street 2Q forecasts on surge in sales, profitBlockbuster hepatitis C medicine Harvoni lifted Gilead Sciences’ second-quarter
Gilead beats Street 2Q forecasts on surge in sales, profit
Salon.com / Posted a month ago
Blockbuster hepatitis C medicine Harvoni lifted Gilead Sciences’ second-quarter profit by 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Gilead Sciences Inc., based... Read more
156 related stories
1m
Reuters
Gilead second quarter profit beats Wall Street, 2015 sales outlook raisedGilead Sciences Inc (GILD.O) said on Tuesday its quarterly net profit rose 32 p
Gilead second quarter profit beats Wall Street, 2015 sales outlook raised
Reuters / Posted a month ago
Gilead Sciences Inc (GILD.O) said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to... Read more
7 related stories
1m
FOX Business
Gilead 2Q Profit Beats Wall Street, 2015 Sales Outlook RaisedGilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, d
Gilead 2Q Profit Beats Wall Street, 2015 Sales Outlook Raised
FOX Business / Posted a month ago
Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between... Read more
7 related stories
1m
Market Watch
Gilead sales soar on Hep-C drugs, beat estimatesGilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, g
Gilead sales soar on Hep-C drugs, beat estimates
Market Watch / Posted a month ago
Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni. For the year, the... Read more
7 related stories
1m
Market Watch
Gilead rallies after earnings beat Wall Street's expectationsShares of Gilead Sciences Inc. GILD, +2.29% rallied in Tuesday's extended trade
Gilead rallies after earnings beat Wall Street's expectations
Market Watch / Posted a month ago
Shares of Gilead Sciences Inc. GILD, +2.29% rallied in Tuesday's extended trade after the biotechnology giant turned in quarterly results that far exceeded expectations. Gilead reported its second-quarter earnings rose to $4.49 billion, or $2.92 a... Read more
1m
Worcester Telegram & Gazette
US stocks rise; earnings outpace China worriesU.S. stocks rose Tuesday, rebounding from their longest losing streak since Jan
US stocks rise; earnings outpace China worries
Worcester Telegram & Gazette / Posted a month ago
U.S. stocks rose Tuesday, rebounding from their longest losing streak since January, amid better-than-forecast earnings and as Chinese equities pulled back from a selloff.United Parcel Service Inc. advanced 5 percent after posting profits that beat... Read more
27 related stories
m
Business Wire
Gilead annuncia alcune promozioniFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ha an
Gilead annuncia alcune promozioni
Business Wire / Posted 1 months ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) ha annunciato oggi la promozione del Dottor William Lee alla carica di vicepresidente esecutivo del reparto Ricerca e di Brett Pletcher alle cariche di vicepresidente esecutivo... Read more
15 related stories
m
Business Wire
Gilead maakt promoties van leidinggevenden bekendFOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) h
Gilead maakt promoties van leidinggevenden bekend
Business Wire / Posted 1 months ago
FOSTER CITY, Californië--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) heeft vandaag de promotie bekendgemaakt van William Lee, PhD, tot Executive Vice President Research, en Brett Pletcher tot Executive Vice President en General Counsel. Dr.... Read more
17 related stories
m
TribLIVE
Dorfman: Apple, Gilead and Hibbett display growth, valueIn the stock market, growth managers and value managers often see themselves as
Dorfman: Apple, Gilead and Hibbett display growth, value
TribLIVE / Posted 1 months ago
In the stock market, growth managers and value managers often see themselves as warring camps. Value managers look for cheap stocks. Growth managers look for rapidly rising earnings. Yet many of the best picks made by managers in either camp display... Read more
m
TheStreet.com
Gilead (GILD) Is Today's Water-Logged And Getting Wetter StockGILD traded below its daily resistance level (quality: 73 days, meaning that th
Gilead (GILD) Is Today's Water-Logged And Getting Wetter Stock
TheStreet.com / Posted 1 months ago
GILD traded below its daily resistance level (quality: 73 days, meaning that the stock is crossing a resistance level set by the last 73 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal). GILD's very... Read more
27 related stories
m
TheStreet.com
Gilead Sciences (GILD) Stock Gains as Japan Approves Harvoni TreatmentHarvoni, along with Gilead's other hepatitis C treatment regiment Sovaldi, are
Gilead Sciences (GILD) Stock Gains as Japan Approves Harvoni Treatment
TheStreet.com / Posted 1 months ago
Harvoni, along with Gilead's other hepatitis C treatment regiment Sovaldi, are two of Gilead's most profitable treatments and combined represented about 60% of the company's revenue, about $4.55 billion, in first quarter this year. "Today's approval... Read more
7 related stories
m
Zero Hedge
The Stock Market's Ugly Truth - Only 6 Stocks MatterWhen we first exposed the shockingly dire lack of breadth in US equity markets,
The Stock Market's Ugly Truth - Only 6 Stocks Matter
Zero Hedge / Posted 1 months ago
When we first exposed the shockingly dire lack of breadth in US equity markets, it was shrugged off by the mainstream media as yet another 'worry' in the wall to climb. It seems, however, that facts inevitably force their way to the surface and so... Read more
m
Japan Today
Bristol-Myers wins approval for 1st hepatitis C type 3 drug ‹ Japan TodayAn experimental drug for one of the hardest-to-treat types of hepatitis C has b
Bristol-Myers wins approval for 1st hepatitis C type 3 drug ‹ Japan Today
Japan Today / Posted 1 months ago
An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly — for patients with the... Read more
6 related stories
m
The China Post
Bristol-Myers wins approval for 1st hepatitis C type 3 drug TRENTON, N.J., AP An experimental drug for one of the hardest-to-treat types
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
The China Post / Posted 1 months ago
TRENTON, N.J., AP An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration (FDA) of the U.S., adding to the surge of... Read more
6 related stories
m
Market Watch
Biogen shares plunge 22% after outlook slashedShares in drug maker Biogen Inc. fell 22% on Friday, losing roughly $20 billion
Biogen shares plunge 22% after outlook slashed
Market Watch / Posted 1 months ago
Shares in drug maker Biogen Inc. fell 22% on Friday, losing roughly $20 billion in market value, after the company reported a sharp slowdown in sales growth for its flagship multiple-sclerosis pill and slashed its full-year revenue forecast. It was... Read more
4 related stories
m
Reuters
FDA approves Sanofi/Regeneron cholesterol drug with limitsFrench drugs firm Sanofi's logo is pictured inside the company's headquarters d
FDA approves Sanofi/Regeneron cholesterol drug with limits
Reuters / Posted 1 months ago
French drugs firm Sanofi's logo is pictured inside the company's headquarters during the company's 2014 annual results presentation in Paris February 5, 2015. WASHINGTON The U.S. Food and Drug Administration approved a potent new... Read more
102 related stories
m
The Register NorthJersey.com
Bristol-Myers wins approval for 1st hepatitis C type 3 drugTRENTON - An experimental drug for one of the hardest-to-treat types of hepatit
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
The Register NorthJersey.com / Posted 1 months ago
TRENTON - An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective but extremely costly - for patients with the... Read more
261 related stories
m
Quincy Herald-Whig
Bristol-Myers wins approval for 1st hepatitis C type 3 drugTRENTON, N.J. (AP) - An experimental drug for one of the hardest-to-treat types
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
Quincy Herald-Whig / Posted 1 months ago
TRENTON, N.J. (AP) - An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective but extremely costly - for patients... Read more
261 related stories
m
Daily Herald
Bristol-Myers wins approval for 1st hepatitis C type 3 drugTRENTON, N.J. -- An experimental drug for one of the hardest-to-treat types of
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
Daily Herald / Posted 1 months ago
TRENTON, N.J. -- An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective but extremely costly - for patients with... Read more
261 related stories
More

People in this news